Literature DB >> 223177

Reflections on the topics: EEG frequency bands and regulation of vigilance.

S Kubicki, W M Herrmann, K Fichte, G Freund.   

Abstract

A critical analysis of quantitative pharmaco-electroencephalography begins with parametrization into variables. The determination of frequency bands according to clinical criteria should be reconsidered. Alternatives may be the determination of factor scores or the definition of frequency bands based on factor analysis. If the latter procedure is used, the clinical alpha-band is subdivided into a lower (alpha 1F = 8,5-10.5 HZ) and an upper (alpha 2F = 10.5-12.5 HZ) part. Furthermore parts of the clinical theta-band (and the delta-band are combined into the delta F-band (1.5-6.0 HZ), for awake healthy volunteers with an occipital alpha-rhythm. Existing concepts of vigilance for the awake stages are not contradictory to the following observations: the factor structure of EEG relative power spectrum variables shows a negative correlation of slow alpha-frequencies with those in the delta F- and beta 3F-band. There is also a negative correlation between slow and fast alpha-wave relative power values.

Mesh:

Substances:

Year:  1979        PMID: 223177     DOI: 10.1055/s-0028-1094615

Source DB:  PubMed          Journal:  Pharmakopsychiatr Neuropsychopharmakol        ISSN: 0031-7098


  50 in total

1.  The "silent" imprint of musical training.

Authors:  Carina Klein; Franziskus Liem; Jürgen Hänggi; Stefan Elmer; Lutz Jäncke
Journal:  Hum Brain Mapp       Date:  2015-11-05       Impact factor: 5.038

Review 2.  The status of spectral EEG abnormality as a diagnostic test for schizophrenia.

Authors:  Nash N Boutros; Cynthia Arfken; Silvana Galderisi; Joshua Warrick; Garrett Pratt; William Iacono
Journal:  Schizophr Res       Date:  2007-12-21       Impact factor: 4.939

3.  EEG source imaging during two Qigong meditations.

Authors:  Pascal L Faber; Dietrich Lehmann; Shisei Tei; Takuya Tsujiuchi; Hiroaki Kumano; Roberto D Pascual-Marqui; Kieko Kochi
Journal:  Cogn Process       Date:  2012-05-05

4.  Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease.

Authors:  Lorena R R Gianotti; Gabriella Künig; Pascal L Faber; Dietrich Lehmann; Roberto D Pascual-Marqui; Kieko Kochi; Ursula Schreiter-Gasser
Journal:  Psychopharmacology (Berl)       Date:  2008-04-30       Impact factor: 4.530

5.  Functional brain network efficiency predicts intelligence.

Authors:  Nicolas Langer; Andreas Pedroni; Lorena R R Gianotti; Jürgen Hänggi; Daria Knoch; Lutz Jäncke
Journal:  Hum Brain Mapp       Date:  2011-05-09       Impact factor: 5.038

6.  EMOTION-PROCESSING BIASES AND RESTING EEG ACTIVITY IN DEPRESSED ADOLESCENTS.

Authors:  Randy P Auerbach; Jeremy G Stewart; Colin H Stanton; Erik M Mueller; Diego A Pizzagalli
Journal:  Depress Anxiety       Date:  2015-05-29       Impact factor: 6.505

7.  EEG-tomographic studies with LORETA on vigilance differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil.

Authors:  M Saletu; P Anderer; G M Saletu-Zyhlarz; M Mandl; O Arnold; J Zeitlhofer; B Saletu
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

8.  Electroencephalography Source Functional Connectivity Reveals Abnormal High-Frequency Communication Among Large-Scale Functional Networks in Depression.

Authors:  Alexis E Whitton; Stephanie Deccy; Manon L Ironside; Poornima Kumar; Miranda Beltzer; Diego A Pizzagalli
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-07-13

9.  Electrophysiological Neuroimaging using sLORETA Comparing 22 Age Matched Male and Female Schizophrenia Patients.

Authors:  Andy R Eugene; Jolanta Masiak; Jacek Kapica; Marek Masiak; Richard M Weinshilboum
Journal:  Hosp Chron       Date:  2015

10.  Comparison of simultaneously recorded [H2(15)O]-PET and LORETA during cognitive and pharmacological activation.

Authors:  Alex Gamma; Dietrich Lehmann; Edi Frei; Kazuki Iwata; Roberto D Pascual-Marqui; Franz X Vollenweider
Journal:  Hum Brain Mapp       Date:  2004-06       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.